Mathangi Gopalakrishnan, MPharm, PhD, is an Associate Professor in the Department of Practice, Science, and Health Outcomes Research at the University of Maryland School of Pharmacy
Mathangi Gopalakrishnan, MPharm, PhD
Associate Professor
Department of Practice, Science, and Health Outcomes Research
University of Maryland School of Pharmacy
E-mail: mgopalakrishnan@rx.umaryland.edu
Postdoctoral – Accepting applications for a postdoctoral position in pharmacometrics at the Center for Translational Medicine
PhD/MS – Not currently recruiting
Education
PhD, Statistics, University of Maryland, Baltimore County
MS, Statistics, University of Maryland, Baltimore County
MPharm, Birla Institute of Technology & Science, Pilani, Rajasthan, India
BPharmacy (Honors), Birla Institute of Technology & Science, Pilani, Rajasthan, India
Research Interests
Pharmacometrics, precision therapeutics, predictive analytics, real world data, and drug development
Current Projects
Research in Gopalakrishnan Lab broadly focuses on the following related areas: pharmacometrics, precision therapeutics, predictive analytics, real world data, and drug development.
We utilize fundamental principles of clinical pharmacology (pharmacokinetics (PK)/pharmacodynamics (PD)), advanced statistical (frequentist and Bayesian) methods (modeling and simulation) and Artificial Intelligence (AI/ML) techniques to improve clinical and therapeutic outcomes for patients, especially vulnerable populations.
Gopalakrishnan lab has designed and conducted prospective, real-world clinical pharmacokinetic (PK) trials for anti-epileptics/anti-microbials in continuous renal replacement therapy (CRRT) patients with the goal to develop individualized antiepileptic regimen for CRRT patients. We have worked on using real world data (electronic health records, prospective pragmatic clinical trials) in the areas of neonatal opioid withdrawal syndrome (NOWS), and anti-coagulants in pediatrics to inform optimal dosing. Currently, we are involved in design and analysis of pharmacokinetic-pharmacodynamic (PD) studies for nutritional supplements and low-calorie artificial sweeteners in pregnant and postpartum women to answer questions on optimal dosing of the nutritional supplements.
Additional areas of research include: models for disease progression (e.g: schizophrenia, binge-eating disorders), AI/ML approaches to identify biomarker-endpoint relationship in medical countermeasure development, innovative quantitative methods for trial design/analysis and predictive analytics in transfusion decision making. The Gopalakrishnan lab works collaboratively with academic medical institutions across the country.